Corcept Therapeutics Q3 2026 Earnings Conference Call - CORCEPT THERAPEUTICS INC

Explicit Guidance:

• Reiterated full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.
• Expect annual revenue for the Cushing syndrome business to reach at least $2 billion by the end of 2030.
• Anticipate annual revenue for the Cushing syndrome business to grow between $3 billion and $5 billion by 2030 upon availability of the Relacorilant launch.
• Project Lithioly (Livoire/Lifiole) to generate more than $1 billion in annual revenue in the future.

Business-Segment Outlook:

• Endocrinology: Anticipate accelerating patient screening, diagnosis, and treatment for hypercortisolism as the American Diabetes Association (ADA) and American Association of Clinical Endocrinology (AACE) recommendations are incorporated into clinical practice.
• Oncology (Ovarian Cancer): Expect Lithioly to transition to earlier lines of therapy (earlier in treatment course) as physician confidence grows and BELLA trial data supports early intervention; anticipate achieving market leadership in platinum-resistant ovarian cancer.
• Pipeline Expansion: Anticipate a potential five-fold increase in the patient population treatable by Relacorilant if successful results are achieved in additional indications (endometrial, pancreatic, prostate).
• New Indications: Target expansion into pancreatic cancer (first-line treatment), endometrial cancer (earlier stage), prostate cancer (early-stage), and MASH (steatohepatitis).
• Combination Strategies: Plan to utilize Relacorilant and Reliqualant in combinations with anti-cancer agents (chemotherapy, immunotherapy, ADCs) and androgen receptor blockers (e.g., enzalumide) to enhance efficacy across solid tumors.

Market and Competitive Outlook:

• Competitive Landscape: Anticipate continued relevance of Lithioly despite emerging competitors (e.g., Genmab/RENA-S) due to its differentiated mechanism of action (glucocorticoid receptor antagonism), immune system modulation, and safety profile (non-chemotherapy, non-ADC, no biomarker screening required).
• Market Dynamics: Expect the "uncured" nature of platinum-resistant ovarian cancer to drive sustained demand for differentiated therapies and combination regimens.
• Adoption Trends: Project rapid adoption of Lithioly as a standard-of-care add-on to Bevacizumab (based on BELLA trial A results) and increasing repeat prescribing rates.
• Diagnostic Paradigm Shifts: Anticipate a structural shift in diabetes management where screening for hypercortisolism becomes standard for patients with difficult-to-treat diabetes, expanding the addressable market for cortisol modulation therapies.

Macro / Industry Outlook:

• Regulatory Timeline: Awaiting FDA decision on the resubmitted New Drug Application (NDA) for Relacorilant in Cushing syndrome by the PDUFA date of December 17, 2026.
• Clinical Guidelines: Expect ongoing clinical study results (BELLA, TRIDENT, SYNERGY, ALS) to be NCCN guideline-enabling and influence future development decisions by the end of next year (2027).
• Pricing/Commercial Strategy: No specific price erosion assumptions disclosed; management emphasizes volume growth and patient identification over pricing changes as primary revenue drivers for 2026.
• Dosing Optimization: Planning a Phase II trial for Miracoralin (MASH) to optimize dosing from twice-weekly to daily (100 mg) with an intermittent schedule (3 weeks on, 1 week off) to maximize liver fat reduction while minimizing ALT rises.

Strategic Initiatives:

• Product Launches:
  • Relacorilant: Pending FDA approval by December 17, 2026; anticipated launch to treat treatment-naive patients and expand the addressable market beyond current Corlin users.
  • Lithioly: Ongoing broad adoption across specialties (gynecologists, oncologists) and settings (academic, community); focus on shifting treatment lines earlier.
  • Miracoralin: Initiating a Phase II trial for MASH in early 2027 to evaluate higher daily dosing; planning a Phase III trial for ALS next year (2027).
• Clinical Trials:
  • BELLA Trial: Arm B (platinum-sensitive ovarian cancer) nearing enrollment completion; Arm C (endometrial cancer) enrollment completed.
  • TRIDENT Trial: Evaluating Relacorilant as first-line treatment for pancreatic cancer.
  • SYNERGY Study: Phase 1b study of Relacorilant + Nabolimab (PD-1 immunotherapy) in solid tumors; results expected end of next year.
  • Prostate Cancer Trial: Randomized Phase II trial of Relacorilant + Enzalumide enrolling now; results expected end of next year.
• Commercial Expansion: Focus on educational initiatives with medical societies (ADA, AACE) to integrate hypercortisolism screening into standard care.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Final FDA approval for Relacorilant is contingent on the PDUFA decision; no guarantees on labeling or timeline beyond the date.
• Clinical Trial Outcomes: Future growth relies on successful data readouts from BELLA, TRIDENT, SYNERGY, and ALS trials by the end of next year.
• Competitive Entry: Potential impact from new drugs in the ovarian cancer space (e.g., Genmab/RENA-S), though management expects Lithioly to maintain relevance via combination strategies.
• Implementation Lag: Time required to incorporate scientific advances into new standards of care and physician prescribing habits.
• Safety/Toxicity: Monitoring for potential adverse events (e.g., ALT rises) during dosing optimization for Miracoralin, though current data shows high tolerability.

Management Tone on the Future:

• Confidence Level: High confidence in revenue growth for 2026 (reiterated guidance despite strong current performance) and long-term revenue potential ($3–$5B by 2030 for Cushing).
• Strategic Outlook: Describes the GR antagonism platform as having "enormous potential" to treat any solid tumor expressing glucocorticoid receptors; views early intervention as a key differentiator.
• Hedges: Management reiterates that actual results may differ from forward-looking statements due to risks and uncertainties detailed in SEC filings; disclaims duty to update statements.
• Change vs. Prior Guidance: Reiterated existing guidance without raising it, citing a probabilistic approach where the midpoint represents their "best thinking" despite strong quarterly results.